ClinicalTrials.gg
CompletedNCT05894928Updated Sep 26, 2023

A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants

A Phase 1 interventional study of LOXO-783 and Cholestyramine in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-26.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jul 2023, 3 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this study is to conduct blood tests to measure how much LOXO-783 is in the bloodstream and how the body handles and eliminates LOXO-783 when administered alone or in combination with cholestyramine in healthy participants. The study will also evaluate the safety and tolerability of LOXO-783 with and without cholestyramine. Participation could last up to 63 days including screening period.

02

Conditions studied

  • Healthy

Keywords

  • Cholestyramine
  • LOXO-783
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy status as defined by the absence of evidence of any active or chronic disease
  • (BMI): 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive

Exclusion criteria

Exclusion Criteria:

  • Females who are lactating or of
  • history of any drug sensitivity, drug allergy, or food allergy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    LOXO-783 alone

    Single dose of LOXO-783 administered orally.

    Drug: LOXO-783

  • Experimental
    LOXO-783 + Cholestyramine 1 hour post dose

    Single dose of LOXO-783 administered orally followed by a single dose of cholestyramine administered orally after 1 hour.

    Drug: LOXO-783 · Drug: Cholestyramine

  • Experimental
    LOXO-783 + Cholestyramine 4 hours post dose

    Single dose of LOXO-783 administered orally followed by a single dose of cholestyramine administered orally after 4 hours.

    Drug: LOXO-783 · Drug: Cholestyramine

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LOXO-783

    PK: Cmax of LOXO-783

    Time frame: Predose on Day 1 upto 96 hours postdose of each treatment period

  2. PK: Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUC[0-inf]) of LOXO-783

    PK: AUC(0-inf) of LOXO-783

    Time frame: Predose on Day 1 upto 96 hours postdose of each treatment period

07

Study locations

1 site
  • Labcorp Clinical Research Unit
    Dallas, Texas 75247, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Jul 2023, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2023
First posted
Jun 8, 2023
StartActual
Jun 7, 2023
Primary completionActual
Jul 9, 2023
CompletionActual
Jul 9, 2023
Last update
Sep 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05894928
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
Jun 8, 2023
Start date
Jun 7, 2023
Primary completion
Jul 9, 2023
Completion
Jul 9, 2023
Last update
Sep 26, 2023

Study contacts

Yingying Guo-Avrutin, MD; PhD
study director · Loxo Oncology, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mutant-selective PI3K-alpha H1047R Inhibitor LOXO-783 · Cholestyramine Resin

Start the discussion